Key clinical point: A high percentage of sickle cell patients prescribed hydroxyurea stop taking the drug.
Major finding: More than 34% of patients prescribed the drug stopped taking it.
Study details: Analysis of clinical questionnaires completed by 224 outpatients and electronic medical records.
Disclosures: Dr. Minniti disclosed relationships with Novartis, Global Blood Therapeutics, Teutona, Bluebird Bio, GBT and Bayer.
Minniti C, et al. Abstract no. JSCDH-D-19-00058. Foundation for Sickle Cell Disease Research Symposium; Fort Lauderdale, Fla.; June 9, 2019.